Investors & Media

Corporate Overview

Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development. The Company’s pipeline includes BDC-3042, a first-in-class agonist antibody that activates macrophages by targeting Dectin-2, and BDC-4182, a next-generation Boltbody™ Immune Stimulating Antibody Conjugate (ISAC) clinical candidate targeting Claudin 18.2. BDC-3042 is currently in a Phase 1 dose escalation trial that includes patients with any of 6 different solid tumor types. BDC-4182 is supported by strong in vitro and in vivo data demonstrating potent anti-tumor activity, and activities are underway to support the initiation of clinical trials in 2025. Bolt Biotherapeutics is also developing additional Boltbody™ ISACs in strategic collaborations with leading biopharmaceutical companies.

News

November 12, 2024

Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateRead More

November 7, 2024

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual MeetingRead More

September 4, 2024

Bolt Biotherapeutics Announces Changes to its Board of DirectorsRead More

View All News Releases

Events

November 6 - November 10, 2024

2024 Society of Immunotherapy of Cancer (SITC) Annual Meeting Read More

September 9, 2024 at 7:00 AM EDT

H.C. Wainwright 26th Annual Global Investment Conference Read More

September 6, 2024 at 7:00 AM EDT

Morgan Stanley 22nd Annual Global Healthcare Conference Read More

View All Upcoming Events